20 Apr 2020 07:00
PDMR Dealing and Additional Listing
April 20, 2020
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 119,414 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the Employee Share Option Scheme and the 2018 Long Term Incentive Plan . Of these, Dr. Rob Quinn, Chief Financial Officer, exercised 89,054 share options at a weighted average price of £1.23, the majority of which were awarded on him joining the Company three years ago.
Following this exercise Dr. Quinn holds a further 677,823 options in the Company.
Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on April 23, 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 82,796,259. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||||
a) | Name | Rob Quinn
| ||||||
2. | Reason for the notification | |||||||
a) | Position / status | Chief Financial Officer
| ||||||
b) | Initial notification / Amendment | Initial notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Silence Therapeutics plc
| ||||||
b) | LEI | 213800SSURRJBX85SQ91
| ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument
Identification code | Exercise of share options under the Employee Share Option Scheme and the 2018 Long Term Incentive Plan
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
| ||||||
b) | Nature of the transaction | Exercise of Options | ||||||
c) | Prices(a) and volume(s) |
| ||||||
d) | Aggregated information - Aggregated volume - Price |
89,054 options at weighted average price of £1.23 | ||||||
e) | Date of the transaction | 20 April 2020
| ||||||
f) | Place of the transaction | Outside a trading venue
| ||||||
Enquiries:
Silence Therapeutics plc Iain Ross, Executive Chairman Dr Rob Quinn, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
| Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company's future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit: https://www.silence-therapeutics.com/